No Data
No Data
Yunnan Baiyao Group (000538.SZ) has launched new toothpaste products in recent years, such as High Altitude Liulan and Jing Shuang Peppermint.
On July 11th, Gelonhui reported that Yunnan Baiyao Group (000538.SZ) stated on the investor communication platform that the company has launched new toothpaste products such as Gaodi Liulan and Jinshuang Mint in recent years, which are made with carefully selected soft abrasives, rich in foam, and have a dense paste that can gently clean teeth.
Yunnan Baiyao Group (000538.SZ): The sales revenue from Yunnan Baiyao aerosol contributed more than 1.7 billion yuan, with a year-on-year growth of 15.27%.
Yunnan Baiyao Group (000538.SZ) stated on the investor interactive platform that the sales revenue of Yunnan Baiyao aerosol contributed over 1.7 billion yuan, an increase of 15.27% year-on-year. Sales revenue for Yunnan Baiyao patches, Yunnan Baiyao ointment, Yunnan Baiyao (powder), and Yunnan Baiyao capsules exceeded 100 million yuan. Among them, the sales revenue of Yunnan Baiyao ointment exceeded 900 million yuan, the sales revenue of Yunnan Baiyao capsules exceeded 600 million yuan, and the sales revenue of Yunnan Baiyao (powder) and Yunnan Baiyao patches exceeded 300 million yuan. Yunnan Baiyao aerosol, functions: promoting blood circulation and removing blood stasis, reducing swelling and relieving pain. Used for sprains and bruises, blood stagnation pain, and muscle soreness.
Yunnan Baiyao Group (000538.SZ): is conducting second-phase development work on Gongxue Ning Capsules, Qixue Kang, and Yunnan Baiyao Capsules.
Yunnan Baiyao Group (000538.SZ) stated on the investor platform that the company is conducting second development work for Gongxue Ning Capsules, Qixue Kang Capsules, and Yunnan Baiyao Capsules. In 2023, the clinical observation study project of Gongxue Ning Capsules for the treatment of uterine bleeding completed 1791 cases of enrollment, and is expected to obtain clinical trial report by the end of 2024. The second development of Qixue Kang, which is used to improve various discomfort symptoms such as qi-blood stasis in patients, has been completed. The clinical research project to improve the health of the heart and blood vessels has completed 70% of patient enrollment, and the results of some of the subjects who have completed the trial have been statistically analyzed preliminarily showing the effectiveness of the treatment.
Yunnan Baiyao Group (000538.SZ): Yunnan Baiyao toothpaste will have a domestic market share of 24.6% in 2023.
On July 4, Gelunhui reported that in the field of oral care, Yunnan Baiyao Group is expected to maintain its first market share of 24.6% domestically in 2023, according to Nielsen retail research data YTD2312. In the 2023 November 11 shopping festival-related period, the health products business group achieved multiple firsts: Yunnan Baiyao Tmall toothpaste official flagship store achieved a breakthrough with single-store sales exceeding 100 million yuan for the first time, becoming the first flagship store to break 100 million yuan in sales with a single toothpaste product; it also won the first place on Douyin's toothpaste best-seller list and the Douyin brand toothbrush explosion list.
These 4 Measures Indicate That Yunnan Baiyao GroupLtd (SZSE:000538) Is Using Debt Safely
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the permanent loss of capital.' It's only natural to consider a company's balance sheet wh
Yunnan Baiyao Group (000538.SZ) plans to introduce the antibody drug project KA-1641.
On June 27, 2024, Yunnan Baiyao Group (stock code: 000538.SZ) announced that the tenth board of directors held the seventh meeting on that date and approved the proposal on introducing the KA-1641 project. The company agreed to introduce the related patent of the antibody drug KA-1641 (referred to as the "symbol product") from Kangyuan Bochuang Biological Technology (Beijing) Co., Ltd. (referred to as "Kangyuan Bochuang") and conduct research and development, production and commercial activities for the symbol product in the global market. The company signed a "Technology Transfer Agreement" with Kangyuan Bochuang. According to the agreement, Kangyuan ...
No Data